Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Stopping replication, at the beginning

A new pharmacological inhibitor of the Cdc7 protein kinase can block replication initiation without activating the replication checkpoint, thus validating replication initiation as a new target class for cancer cell chemotherapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Cdc7 regulation of DNA replication and checkpoints in normal and tumor cells.

References

  1. Montagnoli, A. et al. Nat. Chem. Biol. 4, 357–365 (2008).

    Article  CAS  Google Scholar 

  2. Bell, S.P. & Dutta, A. Annu. Rev. Biochem. 71, 333–374 (2002).

    Article  CAS  Google Scholar 

  3. Forsburg, S.L. Microbiol. Mol. Biol. Rev. 68, 109–131 (2004).

    Article  CAS  Google Scholar 

  4. Montagnoli, A. et al. J. Biol. Chem. 281, 10281–10290 (2006).

    Article  CAS  Google Scholar 

  5. Vanotti, E. et al. J. Med. Chem. 51, 487–501 (2008).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jackson, P. Stopping replication, at the beginning. Nat Chem Biol 4, 331–332 (2008). https://doi.org/10.1038/nchembio0608-331

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nchembio0608-331

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing